Genmab — April 2020
-
"The study seeks to determine the recommended Phase 2 dose in patients with advanced NSCLC.[5] Enrollment into the Part 2 dose expansion cohorts is ongoing" https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-jnj-6372-for-the-treatment-of-non-small-cell-lung-cancer
-
PS! Hos Genmab angives det at fase 2 er igang
-
Men det samme siger JNJ jo, så CT er ikke opdateret
-
submission i slutning af året...
-
kan de nå at få nok evidens til slutning af året?
-
Genmab: JNJ-61186372 is being investigated in Phase II clinical studies to treat non-small cell lung cancer (NSCLC). Lidt forvirrende, men konklusionen er at der er tro på det.
-
enig, hvorfor skulle de ellers nævnte det på CC
-
der venter potentielt 10% royalties af en ny blockbuster. whats not to like
-
it is also a potential SC candidate , according to Halozyme "In December, Janssen selected for development with ENHANZE
the targets EGFR and cMET on an exclusive basis as part of the bispecific antibody (JNJ-61186372), which is being studied in solid tumors."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind